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The objective of this study was to determine the efficacy of gabapentin as adjunctive therapy in doses required to achieve
the most effective seizure control. There were 2016 patients with partial seizures requiring adjunctive therapy who received
gabapentin at doses up to 3600 mg/day in this open-label, multicenter, 16-week study.
Of the 1055 patients evaluable for efficacy, 573 received gabapentin ≤1800 mg/day and 482 received >1800 mg/day as
the highest dose received. For the overall efficacy evaluable population, the percentage of patients achieving at least a 50%
reduction in seizure frequency was 76.0%; 46.4% of the patients were seizure free. Patients whose highest gabapentin dose did
not require >1800 mg/day had, at baseline, fewer seizures and were receiving fewer concomitant antiepileptic drugs (AEDs)
at baseline than those patients requiring >1800 mg/day. This suggests that patients requiring higher doses of gabapentin were
more refractory to drug treatment at the start of the study. Gabapentin was well tolerated at all doses in this study. The results
of the study demonstrate that gabapentin is effective as adjunctive therapy in patients with partial seizures whose seizures are
inadequately controlled by traditional AEDs.
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INTRODUCTION
The options available for antiepileptic drug (AED)
therapy in the 1990s expanded to include new drugs
such as gabapentin, felbamate, topiramate, lamotrig-
ine, and tiagabine1–4. Monotherapy with conventional
AEDs, such as phenytoin, carbamazepine, valproic
acid, primidone and phenobarbital, does not provide
satisfactory seizure control in 15–20% of patients with
epilepsy5, many of whom experience partial seizures.
Use of conventional AEDs in combination increases
the incidence of adverse events associated with these
drugs, further compromising the quality of life of the
patients. In addition, significant drug–drug interac-
tions occur, which can complicate management of the
patients. New drugs with better side-effect profiles and
greater efficacy are clearly needed to control seizures
in patients with epilepsy.
Gabapentin is a new antiepileptic agent that is struc-
turally related to γ -aminobutyric acid (GABA). Un-
like GABA, gabapentin crosses the blood–brain bar-
rier6, 7, but despite its structural similarity with GABA,
gabapentin does not appear to act through any known
GABA mechanisms. Studies in rats with radiolabeled
gabapentin reveal binding sites for this molecule in the
neocortex and hippocampus, the function of which has
yet to be determined8, 9.
Gabapentin has a good safety profile, as predicted by
its lack of pharmacokinetic interactions: it is not bound
to plasma proteins, is not metabolized, does not induce
liver enzymes, and does not modify plasma concentra-
tions of standard AEDs10. These characteristics make
gabapentin especially promising as adjunctive therapy
in the treatment of refractory epilepsy, and its safety
and efficacy have been demonstrated in several large,
placebo-controlled clinical trials11–13.
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The present study, called STEPS (Study of Neuron-
tin: Titration to Effectiveness and Profile of Safety),
examined the effectiveness of gabapentin when used
as adjunctive therapy and when titrated to doses re-
quired to achieve the most effective seizure con-
trol. This multicenter trial focused particular em-
phasis on obtaining effectiveness data for doses up
to 3600 mg/day in epilepsy patients whose partial
seizures were inadequately controlled with maximally
tolerated doses of a traditional AED regimen. These
doses were achieved by optimizing seizure control for
each individual patient.
This post-approval study involved patients in clini-
cal practice, rather than the more refractory and more
restricted patient populations enrolled in Phase II
and III clinical trials. The purpose of this study was to
corroborate and expand upon the observations of con-
trolled clinical trials, by investigating effectiveness in
a heterogeneous patient population.
MATERIALS AND METHODS
Entry criteria
Patients entering this study were classified as having
partial seizures with or without secondary generaliza-
tion according to the Commission on Classification
and Terminology of the International League Against
Epilepsy14, as determined by seizure history or appro-
priate findings detected by electroencephalography. To
qualify, patients had to have inadequate seizure control
(at least two partial onset—simple and/or complex—
seizures a month when averaged over the previous 3
months) while taking one and no more than two stabi-
lized standard AEDs. Patients were to have been tak-
ing the maximum tolerated dose or be within the rec-
ognized therapeutic serum level on at least one AED,
and AED therapy was to have been stable for at least
30 days prior to entering the study. Male or female
patients over 12 years of age, who were capable of
compliance and were able to follow the instructions
of the investigator, were eligible for this study. Fe-
male patients were not to be pregnant or nursing, and,
if sexually active, female patients were to be practic-
ing reliable methods of contraception. Patients were
excluded from the study who: had demonstrated sen-
sitivity to the drug or its ingredients; were treated with
gabapentin within 30 days prior to the study; had pri-
mary generalized seizures, psychogenic seizures, or a
history of non-epileptic seizures; had a history of a
progressive CNS lesion or progressive encephalopa-
thy; had severe hepatic or renal insufficiency or signif-
icant hematological disease; had taken any other ex-
perimental drugs within the 2 months prior to the trial;
or who had serious or unstable medical or psycholog-
ical conditions that, in the opinion of the investigator,
would have compromised the patient’s participation in
the study. All patients or their legal guardians provided
written informed consent to participate in the study.
Design
This was a multicenter, open-label, 16-week study
conducted by 772 investigators in the United States
and six in Canada. This study was designed to com-
pare the safety and tolerability of gabapentin at doses
of ≤1800 mg/day with those >1800 mg/day (up to a
maximum of 3600 mg/day), when titrated to achieve
the most effective seizure control. It was conducted
in an outpatient setting with the protocol reflecting
usual practice and each patient serving as his/her own
control. All investigators used the same protocol, case
report form, and data collection methods. This study
received institutional review board approval for each
site and study procedures were reviewed at a pre-study
meeting.
Patients were to have six scheduled office visits and
one additional visit, which could have occurred ei-
ther by telephone or in the investigator’s office. At
the first visit (visit 1), physical and neurological ex-
aminations were performed, medical and seizure his-
tories recorded, and a baseline quality-of-life ques-
tionnaire (QOLIE-31) was completed. The baseline
seizure data was retrospective, based on patient reports
of the number and type of seizures which occurred
during the 3 months prior to visit 1.
Patients were to begin gabapentin therapy with
900 mg/day (titrated over a 3-day period in incre-
ments of 300 mg/day). One week after initiation of
gabapentin therapy a follow-up visit was scheduled,
either in the investigator’s office or by telephone. It
is important to note that this was not a fixed-dose
study; the gabapentin dose was increased to 1800,
2400, or 3600 mg/day sequentially during the course
of the study if the patient had one or more seizures at
least 2 days after the previous dose increase had been
reached, or if the investigator deemed it necessary.
Thus, each patient’s dose was determined by his/her
clinical need.
At visits 2–5, seizure and safety assessments were
performed and, if any seizures had occurred at least
2 days after the previous dose increase had been
reached, or if the investigator deemed it necessary, the
dose of gabapentin was increased to 1800 mg/day. If
the patient had already reached 1800 mg/day, then the
dose was increased sequentially to 2400 mg/day and
then to a maximum dose of 3600 mg/day.
If a patient experienced an adverse event related
to gabapentin administration, the dose could be de-
creased to that previously tolerated. If the patient was
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receiving 1800 mg/day at the time of the adverse event,
the gabapentin dose was decreased to 1200 mg/day.
Once the symptoms resolved, the dose was increased
at the investigator’s discretion.
At visit 6, 16 weeks after gabapentin therapy began,
seizure and safety assessments were completed, phys-
ical and neurological examinations performed, and the
patient was to have completed a second quality-of-life
questionnaire. Participation in the study ended with
visit 6.
Patients recorded seizure episodes on a calendar,
and the investigator reviewed these calendars at each
visit and recorded the number and type of seizures that
had occurred since the previous visit.
All concomitant medications were optimized prior
to study entry and kept at a constant dose throughout
the study. Changes were allowed, however, in order to
maintain (not improve) a patient’s condition. No med-
ications were prohibited during the study, with the ex-
ception of experimental drugs.
Patients were able to withdraw from the study at any
time, but every effort was made to have patients com-
plete the study within the bounds of safety and the pro-
visions of informed consent. Patients who withdrew
from the study before completing 16 weeks of ther-
apy had safety and seizure assessments and physical
and neurological examinations performed at the time
of withdrawal.
One year after patients had completed the study, in-
vestigators completed a follow-up questionnaire for
patients who had continued on gabapentin treatment
following the end of the 16-week study period. For
each patient, the investigator recorded the daily dose
of gabapentin, the dosing regimen, daily dose of con-
comitant AEDs, and overall assessments of seizure
control and safety/tolerability of the patient’s current
therapy.
Main outcome measures
Efficacy was evaluated by the change in the num-
ber and percentage of total seizures, the proportion of
patients who were seizure free, and by the physician’s
assessment of seizure control (excellent, good, fair, or
poor) at study completion or dropout. In addition, the
percentage change in seizure frequency and the per-
centage of patients who were seizure free was evalu-
ated for each type of partial seizure.
The percentage change and absolute change from
the retrospective baseline to weeks 13–16 in seizure
frequency by seizure type (simple partial, com-
plex partial, secondarily generalized tonic–clonic) and
overall were determined. The absolute change from
baseline was calculated as the difference in seizure fre-
quency between weeks 13–16 and baseline. A negative
change from baseline represented a decrease in seizure
frequency and was considered favorable.
For each patient, the percentage change from base-
line in overall seizure frequency was calculated as:
100(T − B)/B, where T is the number of seizures re-
ported during weeks 13–16 and B is the average num-
ber of seizures per month at baseline. The responder
rate was calculated for the seizure population as the
proportion of patients with a ≥50% reduction from
baseline in partial seizure frequency during the last
4 weeks of the study (i.e. the proportion of patients for
whom the percentage change from baseline in seizure
frequency indicated a decrease of ≥50%).
The cumulative proportion of patients at or below
each dose level was taken to be the number of patients
who were receiving gabapentin at that or a lower dose
level and had the desired outcome (i.e. seizure free or
responder) divided by the total number of patients in-
cluded in the analysis overall.
Seizure control analysis included all patients who
completed 16 weeks of therapy, missed no more than
20% of the scheduled doses at any visit, were not
treated with gabapentin for at least 3 months prior to
starting the study, and had a least a 3-week duration
between the final visit and the previous visit.
Statistical methods
All data processing, summarization, and analyses were
performed using SAS for UNIX, Version 6.09.
Patient demographics and baseline epilepsy char-
acteristics were summarized descriptively (i.e. mean,
standard error, median, minimum, maximum for con-
tinuous parameters, frequency distributions for cate-
gorical parameters) for all patients who received at
least one dose of study medication.
The percentage change and absolute change in the
number of seizures from baseline to the end of study
weeks 13–16 and the corresponding 95% confidence
interval (for percentage change) were calculated over-
all, as well as for each of the seizure types (simple
partial, complex partial, and secondarily generalized
tonic–clonic).
The percentage of patients who were seizure free
during weeks 13–16 and the corresponding 95% con-
fidence interval were calculated overall, as well as for
each of the seizure types (simple partial, complex par-
tial, and secondarily generalized tonic–clonic).
In addition to evaluating the patients overall, anal-
yses were also performed based on the final dose
(≤1800 mg/day or >1800 mg/day).
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RESULTS
Part 1—Descriptive
There were 2216 patients entered into the study. Safety
analyses were performed on data from all patients tak-
ing at least one dose of study medication and partici-
pating in at least one follow-up contact (n = 2216).
This population was also used for the overall physi-
cian’s assessment of seizure control. Efficacy analyses
were performed on data from all patients who com-
pleted the study, had approximately 16 weeks of ther-
apy, missed no more than 20% of the doses at any visit,
and were not treated with gabapentin within 3 months
prior to the start of the study. The above criteria were
met by 1055 patients, who were therefore evaluable
for efficacy: 573 received gabapentin ≤1800 mg/day
and 482 received >1800 mg/day as the highest dose
during the study (Fig. 1, Table 1). Patients could have
reported more than one seizure type. The distribu-
tion of seizure type at baseline was similar for the
two groups of patients, those who received gabapentin
≤1800 mg/day and those who received>1800 mg/day
as the highest dose (Table 2).
Evaluable for safety
Completed study? n = 577 (26.0%)
Due to AEDs= 236 (10.6%)
Highest dose received
n = 584
≤1800 mg/day
n = 573
>1800 mg/day
n = 482
Evaluable for efficacy
n = 1055
n = 1639 (74.0%)
• Missed no more than 20% of
scheduled doses.
• Not treated with gabapentin for
at least 3 months prior to study.
• At least 3 weeks duration
visit.
between final visit and previous
Yes
Yes
No
No
(n = 2216)
Due to inadequate seizure control = 78 (3.5%)
Due to other reasons = 263 (11.9%)
Fig. 1: Patients evaluable for efficacy analysis.
Table 1: Patient characteristics.
Gabapentin Gabapentin
Characteristic ≤1800 mg/day >1800 mg/day Total
n = 573 n = 482 n = 1055
Age (mean year) 40 37 39
Ethnic origin
Caucasian 459 380 839
Hispanic 43 37 80
Black 53 51 104
Asian 6 5 11
Other 10 7 17
Missing data 2 2 4
Gender
Male 258 236 494
Female 314 246 560
Missing data 1 0 1
The baseline seizure frequency was lower for
the group of patients that required less gabapentin
(≤1800 mg/day) than for the group that required
>1800 mg/day as the highest dose received (Table 3).
Patients in the group that required doses of gabapentin
≤1800 mg/day also were taking fewer concomitant
AEDs at baseline than were patients who required
>1800 mg/day (Table 4).
Part 2—Outcomes
Efficacy During the last 4 weeks of the study, ef-
ficacy evaluable patients experienced an average de-
crease in seizures of 61.0%. During this time, 46.4%
of the patients were seizure free (Table 5). The overall
mean seizure frequency decreased from 17 per month
at baseline to 4.5 during the last 4 weeks of the study.
When the data were analysed over the last 8 weeks
of the study, 634 patients were evaluable for efficacy,
47.2% of whom were seizure free, with a responder
rate of 75.4%. The drop in the number of patients
evaluable for the analyses over the last 8 weeks was a
result of all patients not having a visit during the time
window despite having completed the 16-week study.
The cumulative percentage of patients who were
seizure free is presented in Fig. 2. To achieve seizure
freedom, 33.4% of the total patients (352/1055) re-
quired gabapentin doses ≤1800 mg/day as their high-
est dose during the last 4 weeks of the study, and
46.4% of patients taking any dose up to 3600 mg/day
achieved seizure freedom. The cumulative respon-
der rate is presented in Fig. 3. Nearly half (44.9%)
of patients achieved a 50% reduction in seizure fre-
quency at gabapentin doses ≤1800 mg/day, and for
all doses up to 3600 mg/day the responder rate was
76.0%.
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Table 2: Seizure population: baseline seizure type.
Gabapentin Gabapentin
Seizure type ≤1800 mg/day >1800 mg/day Total
n = 573 n = 482 n = 1055
None/unknown 64 56 120
Simple partial only 90 63 153
Complex partial only 217 200 417
SGTC only 54 37 91
Simple partial + complex partial 59 36 95
Simple partial + SGTC 22 11 33
Complex partial + SGTC 67 79 146
SGTC: secondarily generalized tonic–clonic.
Table 3: Seizure population: baseline seizure frequency.
Gabapentin Gabapentin
Characteristic ≤1800 mg/day >1800 mg/day Total
n = 573 n = 482 n = 1055
Duration of epilepsy (mean year) 17 19 18
Baseline seizure frequency
Mean number per month 14 20 17
Median number per month 4 7 5
Table 4: Concomitant AEDs.
Number of concomitant Gabapentin Gabapentin
AEDs at baseline ≤1800 mg/day >1800 mg/day Total
(number (%) of patients) n = 573 n = 482 n = 1055
1 363 (63) 247 (51) 610 (58)
2 155 (27) 205 (43) 360 (34)
≥3 11 (2) 10 (2) 21 (2)
None/unknown 37 (2) 20 (4) 57 (5)
Table 5: Efficacy analysis.
Gabapentin Gabapentin
≤1800 mg/day >1800 mg/day Total
n = 573 n = 482 n = 1055
Average percentage decrease 71.1% 49.1% 61.0%
in seizures
Percentage seizure free 61.4% 28.4% 46.4%
50% responder rate 83.2% 67.6% 76.0%
Table 6: Mean percentage decrease in seizures from baseline.
Gabapentin Gabapentin
Baseline seizure type ≤1800 mg/day >1800 mg/day Total
n = 573 n = 482 n = 1055
Simple partial 67.0 (90) 37.8 (63) 55.0 (153)
Complex partial 65.0 (217) 43.5 (200) 54.7 (417)
SGTC 77.0 (54) 41.7 (37) 62.7 (91)
Simple partial + complex partial 81.8 (59) 59.5 (36) 73.4 (95)
Simple partial + SGTC 86.0 (22) 78.2 (11) 83.4 (33)
Complex partial + SGTC 69.5 (67) 59.7 (79) 64.2 (146)
SGTC: secondarily generalized tonic–clonic. Patients may have exhibited more than one seizure type.
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Fig. 2: Cumulative percentage of patients who were seizure
free at each dose range of gabapentin.
The mean percentage decrease in seizures from
baseline by seizure type is presented in Table 6 and
the percentage of patients who were seizure free dur-
ing the last 4 weeks of the study by seizure type is
presented in Table 7.
Seizure control provided by gabapentin, as assessed
by the physicians at study completion or dropout, was
judged to be excellent or good for 66.1% (1465/2216)
of the patients.
To confirm the results of the efficacy analysis, a
modified intent-to-treat analysis was performed. To be
eligible for the intent-to-treat analysis, patients had
a total duration while on gabapentin of ≥30 days, a
baseline after day 20, and a final visit between days
30 and 140 with a seizure record at each visit. In ad-
dition, the last visit had to have been ≥14 days after
the previous visit. These criteria for analysis were met
by 1668 patients. For these patients, the responder rate
was 74%, and 44% of the patients were seizure free.
The results of this analysis were consistent with the
results of the efficacy analysis for the evaluable popu-
lation.
Safety The four most commonly reported adverse
events in the efficacy evaluable population (n = 1055)
were: somnolence (14.9%); dizziness (10.0%); asthe-
nia (5.8%); and headache (4.5%). These four events
were identical to the four most commonly reported
events for all 2216 patients participating in the study.
Long-term follow-up Data were returned on
1095 patients for the long-term follow-up,
74.9% (819/1095) of whom were receiving
gabapentin 1 year after completion of the
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Fig. 3: Cumulative percentage responder rate at each dose
range of gabapentin.
study. The daily dose of gabapentin ranged from
300 to 6400 mg/day, with a mean daily dose of
2048 mg/day overall. The majority (86.4%; 701/811
with data) had a TID dosing regimen. At the long-
term follow-up, 88.2% of those patients receiving
gabapentin (723/819) were also receiving at least one
other AED. The most common concomitant AEDs
were carbamazepine (24.7%; 202/818 with data) and
phenytoin (18.4%; 151/818 with data). The most fre-
quently reported combination was carbamazepine and
valproate (4.5%; 37/818 with data). Physicians’ as-
sessment of seizure control 1 year after the completion
of the study was judged to be excellent or good for
80.6% (660/819) of the patients. Safety and tolerabil-
ity was rated as excellent or good in 94.4% (773/819)
of the patients.
DISCUSSION
The results of this study demonstrate that gabapentin is
effective as adjunctive therapy in patients with partial
epilepsy whose seizures are inadequately controlled
by traditional AEDs. For individual patients, efficacy
did not plateau, because the dose of gabapentin was
increased in the event of a lack of complete seizure
control. Rather, efficacy increased incrementally with
each dose, resulting in seizure freedom in additional
groups of patients. At both dose levels,≤1800 mg/day
and >1800 mg/day, a large number of patients who
remained in the trial and were efficacy evaluable were
seizure free during the last 4 weeks of the study.
As this was not a fixed-dose study, but rather
patients were optimized to clinical response,
two clearly different groups of patients emerged.
One group of patients responded to lower doses
(≤1800 mg/day) of gabapentin and a second group
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Table 7: Percentage of patients who were seizure free during the last 4 weeks of the study by seizure type.
Gabapentin Gabapentin
Baseline seizure type ≤1800 mg/day >1800 mg/day Total
n = 573 n = 482 n = 1055
Simple partial 68.9 (90) 27.0 (63) 51.6 (153)
Complex partial 60.4 (217) 30.0 (200) 45.8 (417)
SGTC 74.1 (54) 37.8 (37) 59.3 (91)
Simple partial + complex partial 62.7 (59) 22.2 (36) 47.4 (95)
Simple partial + SGTC 40.9 (22) 54.5 (11) 45.5 (33)
Complex partial + SGTC 53.7 (67) 21.5 (79) 36.3 (146)
SGTC: secondarily generalized tonic–clonic. Patients may have exhibited more than one seizure type.
required higher doses (>1800 mg/day) to achieve a
response. Analysis of the baseline characteristics of
the patients according to the dose level of gabapentin
demonstrated that those who required the lower dose
had fewer seizures and were taking fewer AEDs at
baseline than were patients who required higher doses.
The percentage of patients who were seizure free
(46.4%), the responder rate (76.0%), and the average
percentage decrease in seizures (61.0%) were higher
in this study than in previously reported clinical tri-
als11–13. One study with 113 patients evaluable for ef-
ficacy showed a responder rate of 25% for patients re-
ceiving gabapentin 1200 mg/day11. In another study
comprising 245 patients, the responder rate was 22%
for patients receiving gabapentin 900 mg/day and 27%
for those receiving 1200 mg/day13.
In a previous post-approval study, called the Neu-
rontin Evaluation of Outcomes in Neurological Prac-
tice (NEON) Study, the effectiveness of gabapentin as
adjunctive therapy was examined in 114 patients with
complex partial seizures who were not controlled on
existing therapy15. Patients in the NEON study gener-
ally had milder epilepsy than patients who are seen in
tertiary care hospitals, and were generally treated by
community neurologists. Patients received gabapentin
600–2400 mg/day for a 20-week period, in addition
to carbamazepine and/or phenytoin. During the last
8 weeks of the NEON study, 73% of patients with
all types of complex partial and/or secondarily gen-
eralized seizures had a better than 50% reduction in
seizure frequency. Of those patients, 46% were seizure
free. Tolerability of gabapentin was considered to be
excellent or good in 76% of the patients in the NEON
study, with the main adverse events being somnolence
(10%), dizziness (5.4%), and asthenia (3.6%).
The higher responder rates found in the present
study and the NEON study than in Phase III clini-
cal trials could be the result of the higher doses of
gabapentin used in these studies, or could reflect the
real-world population of patients, who tend to be less
refractory than those in Phase II and III clinical trials.
The percentage of patients for whom investigators
judged seizure control to be excellent or good was
highest for patients receiving ≤1800 mg/day and low-
est for patients receiving >3600 mg/day, again re-
flecting patients whose seizures were more easily con-
trolled at the lower doses and patients whose seizures
were more difficult to control, even at higher doses.
The results of this study support the practice of in-
creasing the dose of gabapentin if the patient is still
experiencing seizures at a lower dose: titrating to a
higher dose provides an incremental benefit without
sacrificing tolerability.
The results of the long-term follow-up revealed that
nearly all (96.7%; 788/814 with data) of the patients
who were receiving gabapentin 1 year after comple-
tion of the study were receiving doses ≤3600 mg/day,
and most (88.2%) were receiving gabapentin and at
least one other AED.
Even at the higher doses used in this study, the toler-
ability of gabapentin was good. The most commonly
reported adverse events, somnolence, dizziness, as-
thenia, and headache, were reported with frequencies
similar to those in studies at which gabapentin was ad-
ministered in lower doses11–13. In addition, patients
who received doses of gabapentin >1800 mg/day in
this study did not experience adverse events at signif-
icantly higher rates than did those patients receiving
≤1800 mg/day16.
Several reviews of the literature have analysed the
published data on the new AEDs in order to compare
the efficacy and tolerability of these drugs17, 18. These
analyses suggest that the new drugs provide valuable
alternatives to standard AEDs. Gabapentin is clearly
well tolerated17, and should be considered for patients
taking several drugs or with a history of drug intoler-
ance18.
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